Affimed to Present at Jefferies Virtual Cell Therapy Summit
September 29 2020 - 6:30AM
Heidelberg, Germany, September 29,
2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced that the company’s
management will present at the Jefferies Virtual Cell Therapy
Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time.
A live webcast of the presentation can be
accessed under the “Investors” section of Affimed’s website at
https://www.affimed.com/investors/webcasts_cp/ and will be
available for 30 days following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company is currently enrolling patients into a
registration-directed study of AFM13 for CD30+ relapsed/refractory
peripheral T cell lymphoma and into a Phase 1/2a dose
escalation/expansion study of AFM24 for the treatment of advanced
EGFR-expressing solid tumors. For more information, please visit
www.affimed.com.
Affimed Investor Contact
Alexander FudukidisHead of Investor
RelationsE-Mail: a.fudukidis@affimed.comTel.: (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024